Table 3.
Multivariate linear regression analysis results of the scores of the HADS-A, HADS-D, and HRQoL
Variables | Unstandardized Coefficients | Standardized Coefficients | ||||
---|---|---|---|---|---|---|
B | Standard error | 95% CI | Beta (Descending) | t | p | |
HADS-Aa | ||||||
Constant | 9.447 | 1.008 | 7.466, 11.428 | 9.374 | < .001* | |
Age | − 0.065 | .014 | − .092, − .038 | − 0.230 | − 4.692 | < .001* |
Having an underlying disease | 1.526 | .332 | .874, 2.178 | 0.219 | 4.599 | < .001* |
Support from physicians | − 0.175 | .059 | − .291, − .059 | − 0.142 | − 2.965 | .003* |
HADS-D | ||||||
Constant | 14.443 | 0.143 | 14.162, 14.723 | 101.289 | < .001* | |
Breast reconstruction | 0.626 | 0.252 | .130, 1.121 | 0.116 | 2.482 | .013* |
Having an underlying disease | 0.501 | 0.115 | .099, .903 | 0.115 | 2.451 | .015* |
BRBIa | ||||||
Constant | 59.467 | 6.742 | 46.211, 72.722 | 8.820 | < .001* | |
Chemotherapy | 8.027 | 2.301 | 3.503, 12.552 | 0.180 | 3.488 | .001* |
Having an underlying disease | 7.761 | 2.278 | 3.283, 12.239 | 0.169 | 3.407 | .001* |
Age | − 0.303 | .099 | − .498, − .108 | − 0.166 | − 3.059 | .002* |
Breast reconstruction | 5.589 | 2.758 | .166, 11.011 | 0.102 | 2.026 | .043* |
BRSEFa | ||||||
Constant | 57.389 | 4.227 | 49.079, 65.699 | 5.987 | < .001* | |
Age | 0.403 | .067 | .271, .536 | 0.281 | 5.987 | < .001* |
Having an underlying disease | 5.530 | 1.643 | 2.299, 8.760 | 0.156 | 3.365 | .001* |
Support from husband/partner | − 1.532 | .490 | − 2.494, − .569 | − 0.143 | − 3.129 | .002* |
Belonging to a culture/ethnic minority | 13.531 | 4.694 | 4.303, 22.759 | 0.131 | 2.882 | .004* |
BRSEEa | ||||||
Constant/ | 25.446 | 8.902 | 7.885, 43.006 | 2.859 | .005* | |
Age | .535 | 0.161 | .217, .853 | 0.247 | 3.316 | .001* |
Education | 9.005 | 3.521 | 2.059, 15.951 | 0.191 | 2.558 | .011* |
Support from husband/partner | − 1.703 | .789 | − 3.259, − .147 | − 0.145 | − 2.159 | .032* |
BRFUa | ||||||
Constant | 77.786 | 7.304 | 63.428, 92.144 | 10.649 | < .001* | |
Age | − 0.548 | 0.097 | − 0.739, − 0.357 | − 0.272 | − 5.639 | < .001* |
Having an underlying disease | 11.497 | 2.251 | 7.072, 15.922 | 0.230 | 5.107 | < .001* |
Support from physicians | − 1.503 | .402 | − 2.293, − .713 | − 0.171 | − 3.741 | < .001* |
Chemotherapy | 6.229 | 2.291 | 1.726, 10.732 | 0.127 | 2.719 | .007* |
BRSTa | ||||||
Constant | 28.431 | 1.578 | 25.328, 31.533 | 18.012 | < .001* | |
Having an underlying disease | 8.391 | 1.180 | 6.071, 10.711 | 0.316 | 7.110 | < .001* |
Chemotherapy | 5.118 | 1.174 | 2.811, 7.424 | 0.197 | 4.361 | < .001* |
Support from family and friends | − 1.111 | .366 | − 1.830, − .393 | − 0.135 | − 3.040 | .003* |
Support from physicians | − .631 | .212 | − 1.048, − .215 | − 0.135 | − 2.979 | .003* |
BRBSa | ||||||
Constant | 43.823 | 3.785 | 36.383, 51.262 | 11.579 | < .001* | |
Radiotherapy | 7.040 | 1.255 | 4.572, 9.507 | 0.252 | 5.607 | < .001* |
Belonging to a culture/ethnic minority | 16.237 | 3.718 | 8.928, 23.545 | 0.195 | 4.367 | < .001* |
Age | − 0.226 | 0.054 | − 0.332, − 0.119 | − 0.196 | − 4.159 | < .001* |
Having an underlying disease | 4.680 | 1.304 | 2.118, 7.242 | 0.164 | 3.590 | .018* |
Support from nurses | − .477 | .200 | − .870, − .084 | − 0.110 | − 2.384 | .018* |
BRASa | ||||||
Constant | 28.234 | 1.265 | 25.746, 30.721 | 22.311 | < .001* | |
Radiotherapy | 8.455 | 1.661 | 5.190, 11.721 | 0.265 | 5.090 | < .001* |
Having an underlying disease | 8.462 | 1.457 | 5.597, 11.326 | 0.260 | 5.808 | < .001* |
Chemotherapy | 3.991 | 1.655 | 0.738, 7.244 | 0.125 | 2.411 | .016* |
BRHL | ||||||
Constant | 32.794 | 1.879 | 29,100, 36.487 | 17.449 | < .001* | |
Support from physicians | − .706 | .271 | − 1.238, − .174 | − 0.123 | − 2.608 | .009* |
Belonging to a culture/ethnic minority | 10.450 | 4.430 | 1.744, 19.157 | 0.111 | 2.359 | .019* |
*A level of significance of 0.05
aChemotherapy and support from nurses were significant only in univariate analyses for HADS-A; radiotherapy, Herceptin, support from physicians, and from nurses were significant only in univariate analyses for quality of life – body image. Breast reconstruction, civil status, education, and support from physicians were significant only in univariate analyses for BRSEF. Chemotherapy and support from internet were significant only in univariate analyses for BRSEE. Civil status and support from nurses were significant only in univariate analyses for BRFU. Age was significant only in univariate analysis for BRST. Chemotherapy, civil status, and support from physicians were significant only in univariate analyses for BRBS. Age and support from physicians were significant only in univariate analyses for BRAS
HADS-A, F = 17.551, p < .001, Adjusted R2 = 0.107
HADS-D, F = 5.585, p = .004, Adjusted R2 = 0.020
BRBI, F = 11.067, p < .001, Adjusted R2 = 0.093
BRSEF, F = 21.160, p < .001, Adjusted R2 = 0.164
BRSEE, F = 11.775, p < .001, Adjusted R2 = 0.146
BRFU, F = 24.916, p < .001, Adjusted R2 = 0.184
BRST, F = 23.228, p < .001, Adjusted R2 = 0.173
BRBS, F = 19.798, p < .001, Adjusted R2 = 0.185
BRAS, F = 27.954, p < .001, Adjusted R2 = 0.160
BRHL, F = 6.377, p = .002, Adjusted R2 = 0.024
Hospital, Anxiety, and Depression Scale – Anxiety subscale (HADS-A); Hospital, Anxiety, and Depression Scale – Depression subscale (HADS-D); Health-Related Quality of Life (HRQoL); Quality of life – body image (BRBI); Quality of life – sexual functioning (BRSEF); Quality of life – sexual enjoyment (BRSEE); Quality of life – future perspective (BRFU); Quality of life – systemic therapy side effects (BRST); Quality of life – breast symptoms (BRBS); Quality of life – arm symptoms (BRAS); and Quality of life – upset by hair loss (BRHL)